SECURITIES AND EXCHANGE COMMISSION
|
|
Washington, D.C. 20549
|
|
SCHEDULE 13D/A
|
|
Under the Securities Exchange Act of 1934
|
|
(Amendment No. 4)*
|
|
Myrexis, Inc.
|
|
(Name of Issuer)
|
|
Common Stock, par value $0.01 per share
|
|
(Title of Class of Securities)
|
|
62856H107
|
|
(CUSIP Number)
|
|
Mark Goldstein
First Eagle Investment Management, LLC
1345 Avenue of the Americas
New York, New York 10105
(212) 698-3101
|
|
(Name, Address and Telephone Number of Person
|
|
Authorized to Receive Notices and Communications)
|
|
November 12, 2012
|
|
(Date of Event Which Requires Filing of This Statement)
|
|
CUSIP No. 62856H107
|
SCHEDULE 13D/A
|
Page 2 of 6 Pages
|
1
|
NAME OF REPORTING PERSON
First Eagle Investment Management, LLC
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) x
(b) ¨
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS
AF
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
¨
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
0
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
0
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
0
|
|||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
¨
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.00%
|
|||
14
|
TYPE OF REPORTING PERSON
IA; CO
|
CUSIP No. 62856H107
|
SCHEDULE 13D/A
|
Page 3 of 6 Pages
|
1
|
NAME OF REPORTING PERSON
First Eagle Value in Biotechnology Master Fund Ltd.
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) x
(b) ¨
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS
WC
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
¨
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
0
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
0
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
0
|
|||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
¨
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.00%
|
|||
14
|
TYPE OF REPORTING PERSON
CO
|
CUSIP No. 62856H107
|
SCHEDULE 13D/A
|
Page 4 of 6 Pages
|
Item 5.
|
INTEREST IN SECURITIES OF THE ISSUER
|
|
Paragraphs (a), (c) and (e) of Item 5 are hereby amended and restated in their entirety as follows:
|
||
(a) As of the close of business on November 12, 2012, the Reporting Persons do not have, and may not be deemed to have, beneficial ownership of any Shares.
|
||
(c) Information concerning transactions in the Shares effected by the Reporting Persons since the filing of Amendment No. 3 is set forth in Schedule A hereto and is incorporated herein by reference. Except as otherwise indicated, all of the transactions in Shares listed on Schedule A hereto were effected in the open market.
|
||
(e) November 12, 2012.
|
CUSIP No. 62856H107
|
SCHEDULE 13D/A
|
Page 5 of 6 Pages
|
FIRST EAGLE INVESTMENT MANAGEMENT, LLC
|
||
/s/ Mark Goldstein
|
||
Name: Mark Goldstein
|
||
Title: Senior Vice President
|
||
FIRST EAGLE VALUE IN BIOTECHNOLOGY MASTER FUND LTD.
|
By: | FIRST EAGLE INVESTMENT MANAGEMENT, LLC, | ||||
Its Investment Manager | |||||
By:
|
/s/ Mark Goldstein
|
||||
Name: Mark Goldstein
|
|||||
Title: Senior Vice President
|
CUSIP No. 62856H107
|
SCHEDULE 13D/A
|
Page 6 of 6 Pages
|
Date of Transaction
|
Shares Purchased (Sold)
|
Price per Share ($)
|
11/12/2012
|
(2,500,000)
|
2.7488
|
11/12/2012
|
(99,236)
|
2.7055
|